Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating and $175 PT on Expedia (EXPE) Following Mgmt Meetings; 'Critical Year' for HomeAway
-
Prothena Corp. (PRTA) Commences 2.7M Offering of Ordinary Shares
-
Prothena Corporation plc : Prothena Announces Public Offering of Ordinary Shares
-
Prothena Announces Public Offering of Ordinary Shares
-
Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update
-
Glaukos Corporation (GKOS) PT Raised to $54 at Cantor Fitzgerald; 4Q Results, 4Q Sales Growth, '17 Guidance, All 'Impressive'
-
Cantor Fitzgerald Downgrades The Trade Desk (TTD) to Neutral
-
DepoMed Inc (DEPO) PT Lowered to $19 at Cantor Fitzgerald
-
Freddie Mac Prices $241 Million Multifamily K-Deal, K-J12
-
Cantor Fitzgerald Reiterates Outperform on Ashford Hospitality Trust (AHT) Following 4Q
-
AMAG Pharma (AMAG): Rekynda Data Could Blunt the Impact of Makena Competition - Cantor
-
Shutterstock (SSTK) PT Lowered to $43 at Cantor Fitzgerald Following 4Q Miss
-
Sabra Healthcare REIT Inc. (SBRA) PT Raised to $30 at Cantor Fitzgerald on 4Q FFO Beat; 'Re-Focused on Growth'
-
CardConnect Corp. (CCN) PT Raised to $17 at Cantor Fitzgerald on 'High Annual Revenue Visibility'
-
Cantor Fitzgerald Maintains Neutral Rating and $2 PT on Novavax (NOVA) Following Mixed Q4 Results
-
The Priceline Group (PCLN) PT Raised to $1,850 at Cantor Fitzgerald
-
Shutterstock (SSTK) PT Lowered to $43 at Cantor Fitzgerald
-
Intrepid Potash Announces Fourth Quarter and Full Year 2016 Results
-
Facebook's virtual reality ambitions could be threatened by court order
-
Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
-
Daseke, Inc. and Hennessy Capital Acquisition Corp. II Announce Closing of Merger Transaction
-
Daseke and Hennessy Capital Acquisition Corp. II (HCAC) Close Merger Transaction
-
Daseke, Inc. and Hennessy Capital Acquisition Corp. II Announce Closing of Merger Transaction
-
Cantor Fitzgerld Reiterates Overweight Rating and $1750 PT Ahead of 4Q Report
-
Cantor Fitzgerald Remains Sidelined on Shutterstock (SSTK) Ahead of 4Q Report
-
Cantor Fitzgerald Reiterates Overweight Rating and $55 PT on LTC Properties (LTC) Following 4Q Results
-
Cantor Fitzgerald Adjusts Estimates on Acadia Healthcare (ACHC) Following 4Q
-
Heron Therapeutics (HRTX) PT Lowered to $30 at Cantor Fitzgerald Following $167.3M Capital Raise
-
Cantor Fitzgerald Remains Bullish on eHealth (EHTH) Following 4Q Report
-
Harmony Merger (HRMN) Announces Receipt of Notice of Termination of Merger Agreement from MUNDOmedia
-
Harmony Merger Corp. Announces Receipt of Purported Termination of Merger Agreement from MUNDOmedia
-
BioDelivery Sciences Secures Debt Financing with CRG
-
Global Blood Therapeutics (GBT) Prices Upsized 5.1M Common Stock Offering at $24.50/Share
-
Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public Offering
-
Cantor Fitzgerald Reiterates Overweight Rating and $66 PT on Cerner Corp. (CERN); 'Shares Attractive'
-
Cantor Fitzgerald Reiterates Neutral on Extra Space Storage (EXR) Following 4Q
-
First Take on Verisk Analytics (VRSK) Earnings: Energy Better Than Expected - Cantor
-
Community Health (CYH) PT Raised to $8 at Cantor Fitzgerald
-
Moody's Corp (MCO) PT Raised to $108 at Cantor Fitzgerald Following Strong 4Q16 Results
-
Cantor Fitzgerald Reiterates Neutral Rating and $27 PT on HealthStream (HSTM) Following 'Light' 4Q16 Results
-
Corbus Pharma (CRBP): Notes From KOL Call - Cantor
-
Affiliates of Apollo and HGM Agree to Combine Novitex and SourceHOV with Quinpario Acquisition Corp. 2 to Form Exela Technologies, a Public Company in a Transaction Valued at $2.8 Billion
-
Global Blood Therapeutics (GBT) to Offer $75M in Common Stock
-
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Reiterates Neutral on LifePoint Health (LPNT) After Adjusting Estimates
-
Cantor Fitzgerald Remains Sidelined on National Health Investors (NHI) After Adjusting Estimates
-
Cantor Fitzgerald Reiterates Overweight on Aetna (AET) Following Increased Dividend
-
Cantor Fitzgerald Reiterates Overweight Rating and $21 PT on Abeona Therapeutics (ABEO); Positive ABO-102 Data
-
Cantor Fitzgerald Remains Bullish on Cytokinetics (CYTK)
-
TripAdvisor (TRIP): Chasing Growth Will Pressure Margins - Cantor Fitzgerald

